Kimball Electronics (KE) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
9 Jul, 2026Executive summary
Q1 FY2025 net sales were $374.3 million, down 15% year-over-year, reflecting broad end-market weakness and tough year-over-year comparisons.
Strategic restructuring included divesting non-core AT&M/GES business and integrating medical CMO into core EMS, sharpening focus on key verticals.
Announced closure of Tampa facility by Q1 FY2026, with production shifting to Mexico and Jasper, to streamline operations and invest in core business growth.
Results aligned with expectations, with continued focus on cost control, working capital management, and positive cash flow generation.
Cash from operations reached $45.5 million, supporting debt reduction to a two-year low.
Financial highlights
Q1 net sales were $374.3 million, down 15% year-over-year; excluding AT&M/GES, down 13%.
Gross margin was 6.3%, a 180 bps decline from last year due to lower absorption.
Adjusted operating income was $12.6 million (3.4% of sales), down from $21 million (4.8%) last year.
Adjusted net income was $5.5 million ($0.22 per diluted share); net income was $3.2 million ($0.12 per share), both down sharply year-over-year.
Operating cash flow was $45.5 million; inventory reduced by $147 million year-over-year; borrowings at $245.9 million, lowest in two years.
Outlook and guidance
FY2025 guidance confirmed: net sales $1.44–$1.54 billion, adjusted operating income margin 4–4.5%, capex $40–$50 million.
Q2 revenue expected to decline similarly to Q1, but with margin improvement as restructuring progresses.
Gross margin expected to improve gradually, with more significant gains in the back half of the year.
Additional restructuring charges of $10–14 million anticipated over the next 12 months, including $8–$11 million for the Tampa exit.
Guidance confirmed despite challenging market conditions and major automotive program loss.
Latest events from Kimball Electronics
- Acquisition expands global medical CMO platform, boosting growth and earnings by 2027.KE
M&A announcement15 Jul 2026 - Profitable growth expected as medical and automotive markets drive margin expansion and investment.KE
Company presentation18 May 2026 - Medical-led sequential growth and strong margins support high-end fiscal 2026 outlook.KE
Q3 20266 May 2026 - Raised FY26 guidance and expanded medical focus drive profitable growth outlook.KE
Company presentation20 Mar 2026 - Medical segment growth and facility expansion drive strategic shift and margin improvement.KE
2026 KeyBanc Capital Markets Healthcare Forum19 Mar 2026 - Q2 sales fell 5% but margins and 2026 guidance improved on strong medical growth.KE
Q2 20265 Feb 2026 - Q4 sales dropped 13% as inventory and liquidity improved; 2025 outlook remains cautious.KE
Q4 20241 Feb 2026 - Streamlined operations and global focus drive resilience despite EMS market headwinds.KE
The Stifel 2024 Cross Sector Insight Conference31 Jan 2026 - FY 2025 sales expected to decline 8–14% as focus shifts to automation, medical, and debt reduction.KE
2024 Annual Gateway Conference22 Jan 2026